{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:23Z","timestamp":1786988123044,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.ejphar.2008.02.027","type":"journal-article","created":{"date-parts":[[2008,2,20]],"date-time":"2008-02-20T10:40:38Z","timestamp":1203504038000},"page":"297-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats"],"prefix":"10.1016","volume":"584","author":[{"given":"Sophie","family":"Sarre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Makovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Artusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Caselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Michotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2008.02.027_bb0005","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The functional anatomy of basal ganglia disorders","volume":"12","author":"Albin","year":"1989","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-8993(03)02531-9","article-title":"Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats","volume":"972","author":"Arai","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0015","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.expneurol.2005.08.017","article-title":"Combined blockade of AMPA and NMDA glutamate receptors reduces the levodopa-induced motor complications in animal models of PD","volume":"196","author":"Bibbiani","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0020","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"Blanchet","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0025","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1523\/JNEUROSCI.4262-04.2005","article-title":"Amantadine inhibits NMDA receptors by accelerating channel closure during channel block","volume":"25","author":"Blanpied","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0030","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.20612","article-title":"Non-dopaminergic mechanisms in levodopa-induced dyskinesia","volume":"20","author":"Brotchie","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0035","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1111\/j.1471-4159.2006.03696.x","article-title":"Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats","volume":"96","author":"Carta","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0026-895X(24)23206-5","article-title":"Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease","volume":"57","author":"Dunah","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0045","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1097\/00001756-199412000-00045","article-title":"NMDA receptor blockade reverses motor response alterations induced by levodopa","volume":"5","author":"Engber","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejphar.2008.02.027_bb0050","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0006-8993(00)02339-8","article-title":"Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain","volume":"868","author":"Fisher","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0055","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0006-8993(98)00129-2","article-title":"Differential effects of NMDA and non-NMDA antagonists on the activity of aromatic L-amino acid decarboxylase activity in the nigrostriatal pathway of the rat","volume":"792","author":"Fisher","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0060","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/j.2042-7158.1970.tb08486.x","article-title":"The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates","volume":"22","author":"Fletcher","year":"1971","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s007020170086","article-title":"Co-administration of memantine and amantadine with sub\/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice","volume":"108","author":"Fredriksson","year":"2001","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0070","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.neuroscience.2004.10.016","article-title":"The non-peptidic delta opioid receptor agonist TAN-67 enhances dopamine efflux in the nucleus accumbens of freely moving rats via a mechanism that involves both glutamate and free radicals","volume":"130","author":"Fusa","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2008.02.027_bb0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA receptor antagonists in Parkinson's disease","volume":"102","author":"Hallett","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(98)00393-8","article-title":"Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats","volume":"353","author":"Izurieta-Sanchez","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0014-2999(00)00753-6","article-title":"MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats","volume":"407","author":"Jonkers","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0090","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0006-8993(01)03147-X","article-title":"MK-801 suppresses the L-Dopa-induced increase of glutamate in striatum of hemi-Parkinson rats","volume":"925","author":"Jonkers","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0095","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s007020050125","article-title":"Amantadine attenuates response alterations resulting from repetitive L-Dopa treatment in rats","volume":"105","author":"Karcz-Kubicha","year":"1998","journal-title":"J. Neural. Transm. Suppl."},{"issue":"Suppl.","key":"10.1016\/j.ejphar.2008.02.027_bb0100","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nn936","article-title":"NMDA receptor pathways as drug targets","author":"Kemp","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ana.410280411","article-title":"NMDA receptor antagonists potentiate antiparkinsonian actions of L-Dopa in monoamine-depleted rats","volume":"28","author":"Klockgether","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0110","series-title":"The rat brain \u2014 a stereotaxic atlas of the forebrain and lower parts of the brain stem","author":"K\u00f6nig","year":"1963"},{"key":"10.1016\/j.ejphar.2008.02.027_bb0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","article-title":"Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study","volume":"206","author":"Kornhuber","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0120","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1124\/jpet.104.070235","article-title":"The NR2B-selective antagonist N-methyl-D-aspartate antagonist Ro-25-6981 potentiates the effect of nicotine on locomotor activity and dopamine release in the nucleaus accumbens","volume":"311","author":"Kosowski","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0125","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.expneurol.2004.01.018","article-title":"Antiparkinsonain activity of Ro-25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease","volume":"187","author":"L\u00f6schmann","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.neuropharm.2005.09.002","article-title":"Functional in vitro characterization of CR 3394: a novel voltage dependent N-methyl-D-aspartate (NMDA) receptor antagonist","volume":"50","author":"Losi","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2008.02.027_bb0135","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0006-8993(96)00693-2","article-title":"MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats","volume":"736","author":"Marin","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0140","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1046\/j.1471-4159.1999.721516.x","article-title":"Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats","volume":"72","author":"Miller","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0006-8993(94)90821-4","article-title":"Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism","volume":"662","author":"Mizoguchi","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mds.20654","article-title":"Prevention of levodopa-induced dyskinesias by a selective NR1A\/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin","volume":"21","author":"Morissette","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/syn.20295","article-title":"Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors","volume":"60","author":"Morissette","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.ejphar.2008.02.027_bb0160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mds.10107","article-title":"Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat","volume":"17","author":"Nash","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/exnr.2000.7444","article-title":"Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"165","author":"Nash","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0170","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.expneurol.2004.05.004","article-title":"The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"188","author":"Nash","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0006-8993(95)00924-3","article-title":"Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade","volume":"701","author":"Papa","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0180","series-title":"The Rat Brain in Stereotaxic Coordinates","year":"1986"},{"key":"10.1016\/j.ejphar.2008.02.027_bb0185","first-page":"97","article-title":"Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover","volume":"46","author":"Quack","year":"1995","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00180005","article-title":"Biotransformation of locally applied L-Dopa in the corpus striatum of the hemi-Parkinsonian rat studied with microdialysis","volume":"350","author":"Sarre","year":"1994","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0195","series-title":"Methods in Molecular Biology","first-page":"185","article-title":"Microbore liquid chromatography analysis of monoamine transmitters","volume":"vol. 72","author":"Sarre","year":"1997"},{"key":"10.1016\/j.ejphar.2008.02.027_bb0200","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0149-7634(96)00039-5","article-title":"Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease","volume":"21","author":"Starr","year":"1997","journal-title":"Neurosci. Behav. Rev."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0205","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/exnr.2000.7374","article-title":"Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors","volume":"163","author":"Steece-Collier","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0210","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0361-9230(96)00211-0","article-title":"Inhibitory effect of MK-801 on amantadine-induced dopamine release in rat striatum","volume":"41","author":"Takahashi","year":"1996","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0215","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2008.02.027_bb0220","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1471-4159.1999.0730344.x","article-title":"Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia","volume":"73","author":"Vila","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2008.02.027_bb0225","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0014-2999(88)90110-0","article-title":"In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs: implications for the origin of extracellular DOPAC","volume":"148","author":"Zetterstr\u00f6m","year":"1988","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908001787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908001787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T12:11:58Z","timestamp":1738066318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299908001787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":45,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0014299908001787"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.02.027","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}